GeneSight vs Genomind: Pharmacogenomic Testing Compared

8 min read · Last updated: March 2026 · DecodeMyBio Editorial Team

GeneSight and Genomind Professional PGx Express are two of the most widely used provider-ordered pharmacogenomic panels for psychiatric medications. Both analyze genes that affect how your body metabolizes drugs — but they differ in gene coverage, pricing, clinical evidence, and the number of medications assessed.

This page compares both tests side by side, including their largest clinical trials, and explains how raw data analysis from existing 23andMe or AncestryDNA files offers a different approach to pharmacogenomic insights.

Already have DNA data from 23andMe or AncestryDNA?

You can get pharmacogenomic analysis using data you already own — no new test, no provider order, no insurance billing. DecodeMyBio maps your raw data to published CPIC clinical guidelines across 19 genes and 150+ drug-gene interactions.

Upload your data · View a sample report

What GeneSight and Genomind Test

GeneSight Psychotropic (Myriad Genetics) analyzes 15 genes — 9 pharmacokinetic, 5 pharmacodynamic, and 1 additional (COMT) — covering over 60 psychotropic medications. Pharmacokinetic genes include CYP2D6, CYP2C19, CYP2C9, CYP1A2, CYP3A4, CYP2B6, UGT1A4, UGT2B15, and CES1A1.¹

Genomind Professional PGx Express analyzes 26 genes — both pharmacokinetic and pharmacodynamic — covering 130+ neuropsychiatric medications and over 700 medications in total across all categories.^2,3

Both tests require a cheek swab and a provider order. Genomind also offers a telehealth option where a licensed provider can order the test virtually.²

Side-by-Side Comparison

Information sourced from each company's public materials as of March 2026. Verify current details directly with each provider.

Feature	GeneSight	Genomind PGx Express	DecodeMyBio (raw data)
Genes tested	15¹	26³	19
Medications covered	Over 60 psychotropic¹	130+ neuropsychiatric²	100+ across 3 reports
Provider order required	Yes¹	Yes²	No
Sample type	Cheek swab¹	Cheek swab²	Existing DNA file
Self-pay cost	$330⁴	$599⁵	$49 (Medication Safety) or $59 (Psychiatric)
Medicare Part B	$0 typical⁴	$0 if criteria met⁵	N/A
Turnaround	~3 business days¹	3–5 business days²	Minutes
Guideline basis	Proprietary algorithm¹	Proprietary²	CPIC published guidelines
Uses existing DNA data	No	No	Yes

¹ GeneSight (genesight.com/product/): 9 PK genes + 5 PD genes + COMT. "over 60 mental health medications." Cheek swab, results in "about 3 days."

² Genomind (genomind.com/solutions/pharmacogenetic-testing/): "analyzing 26 genes, offering insights into 130+ neuropsychiatric medications" and "assess over 700 medications." Results in "3-5 days or less."

³ Genomind (genomind.com/solutions/pharmacogenetic-testing/genes/): "Pharmacogenetic testing with Genomind analyzes 26 selected genes."

⁴ GeneSight (genesight.com/cost/): "All patients are eligible for the reduced self-pay option of $330." Medicare Part B: "$0 is the typical out-of-pocket cost."

⁵ Genomind (genomind.com/cost-and-coverage/): "$599 one-time payment when registering." Medicare Part B: "$0 out of pocket if coverage criteria are met."

Clinical Evidence

Both GeneSight and Genomind have published randomized controlled trials (RCTs). Neither test's largest RCT met its primary endpoint.

GeneSight — GUIDED Trial

Greden JF et al. "Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial." J Psychiatr Res. 2019;111:59-67. PMID: 30677646

n = 1,167 outpatients with major depressive disorder
Primary endpoint (Week 8 symptom improvement): 27.2% vs 24.4%, p = 0.107 (not statistically significant)
Secondary: response 26.0% vs 19.9% (p = 0.013); remission 15.3% vs 10.1% (p = 0.007) — both statistically significant

Genomind — Perlis 2020 RCT

Perlis RH et al. "Randomized, controlled, participant- and rater-blind trial of pharmacogenomic test-guided treatment versus treatment as usual for major depressive disorder." Depress Anxiety. 2020;37(9):834-841. PMID: 32383277

n = 304 participants
Primary endpoint (SIGH-D-17 change): no significant difference
Exploratory: fewer patients experienced worsening; treatment concordant with test results was associated with greater likelihood of remission

How Raw Data Analysis Differs

GeneSight and Genomind are provider-ordered clinical laboratory tests. Raw data analysis takes a different approach: it uses existing consumer DNA data from 23andMe, AncestryDNA, or other providers that you have already taken.

Clinical panels: Provider-ordered, clinical laboratory analysis, proprietary reporting algorithms
Raw data analysis: Uses existing consumer DNA, maps to published CPIC guidelines (not proprietary), informational (not diagnostic)

Consumer genotyping arrays cover a defined set of variants and have known limitations — see our limitations page and methodology for details. For high-stakes prescribing decisions, a provider-ordered test may be appropriate.

Regulatory Context

Neither GeneSight nor Genomind is described as FDA-cleared or FDA-approved in their public materials (verified: genesight.com, genomind.com, March 2026).

On November 1, 2018, the FDA issued a safety communication stating that "claims for many genetic tests to predict a patient's response to specific medications have not been reviewed by the FDA" and warning that use "could lead to potentially serious health consequences."⁶ Neither GeneSight nor Genomind was named in the communication.

See what pharmacogenomic analysis looks like with your existing DNA data. Upload your raw data file from 23andMe or AncestryDNA to get your metabolizer phenotypes mapped to CPIC guidelines across 19 genes and 150+ drug-gene interactions.

Upload your data · View a sample report · Compare all testing options

Frequently Asked Questions

Is GeneSight or Genomind better?

No head-to-head clinical trial has compared GeneSight and Genomind. GeneSight tests 15 genes and covers over 60 psychotropic medications with a self-pay cost of $330. Genomind tests 26 genes and covers 130+ neuropsychiatric medications at $599 self-pay. The choice depends on your provider's recommendation, insurance coverage, and which gene panel is most relevant to your medications.

Does insurance cover GeneSight or Genomind?

Medicare Part B typically covers both at $0 out-of-pocket. Commercial insurance coverage varies by plan. UnitedHealthcare updated its commercial policy for multi-gene pharmacogenetic panels effective January 1, 2025, which may affect GeneSight coverage under UHC commercial and individual exchange plans. Medicare Advantage and managed Medicaid plans were not affected by this change.^7,8

Can I use 23andMe data instead of GeneSight or Genomind?

Yes, for informational pharmacogenomic analysis. Services like DecodeMyBio analyze existing raw data from 23andMe, AncestryDNA, and other consumer DNA tests, mapping results to published CPIC clinical guidelines. Consumer genotyping arrays cover a defined set of variants and have known limitations. For high-stakes prescribing decisions, a provider-ordered test may be appropriate. See what to do with your 23andMe raw data for a full walkthrough.

Did GeneSight's clinical trial prove it works?

The GUIDED trial's primary endpoint — symptom improvement at week 8 — was not statistically significant (p = 0.107). Secondary endpoints showed statistically significant improvement in response (p = 0.013) and remission (p = 0.007). Genomind's largest RCT (Perlis et al., 2020) also did not meet its primary endpoint. Both studies found positive signals in secondary or exploratory analyses.

References

GeneSight Product Information — genesight.com/product/. genesight.com
Genomind Professional PGx Express — genomind.com/solutions/pharmacogenetic-testing/. genomind.com
Genomind Gene List — genomind.com/solutions/pharmacogenetic-testing/genes/. genomind.com
GeneSight Pricing — genesight.com/cost/. genesight.com
Genomind Pricing — genomind.com/cost-and-coverage/. genomind.com
FDA Safety Communication, November 1, 2018. fda.gov
Greden JF et al. J Psychiatr Res. 2019;111:59-67. PMID: 30677646
Perlis RH et al. Depress Anxiety. 2020;37(9):834-841. PMID: 32383277
Myriad Genetics on UHC Policy — GlobeNewsWire, Nov 4, 2024. globenewswire.com
Myriad Genetics UHC Update — GlobeNewsWire, Dec 10, 2024. globenewswire.com

Back to all comparisons